Can we personalize treatment for kidney diseases? (17/1062)

 (+info)

Information management to enable personalized medicine: stakeholder roles in building clinical decision support. (18/1062)

 (+info)

What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting? (19/1062)

The new mantra for delivering optimal cancer treatment is "personalized care." This extends beyond the holistic to using germline and somatic tumoral mutations to link a specific therapy to some prognostic or predictive factor which defines a particularly responsive patient subgroup who might benefit most from treatment. Furthermore, inherited polymorphisms have the potential to greatly modulate the side effects of treatment, especially for chemotherapy which has a notoriously narrow therapeutic window.  (+info)

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. (20/1062)

 (+info)

Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. (21/1062)

 (+info)

Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. (22/1062)

 (+info)

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. (23/1062)

 (+info)

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (24/1062)

 (+info)